Pancreatic cancer risk after treatment of Hodgkin lymphoma

Annals of Oncology

Volumn 25, Issue 10, 2014, Pages 2073-2079

  Dores, Graça M ^a,b   Curtis, R E ^a   van Leeuwen, F E ^c   Stovall, M ^d   Hall, P ^e   Lynch, C F ^f   Smith, S A ^d   Weathers, R E ^d   Storm, H H ^g   Hodgson, D C ^h   Kleinerman, R A ^a   Joensuu, H ⁱ   Johannesen, T B ^j   Andersson, M ^k   Holowaty, E J ^l   Kaijser, M ^e   Pukkala, E ^m   Vaalavirta, L ⁱ   Fossa, S D ⁿ   Langmark, F ^j   Travis, L B ^o   Fraumeni, J F ^a   Aleman, B M ^c   Morton, L M ^a   Gilbert, E S ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY OF IOWA   (United States)

^g DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^j CANCER REGISTRY OF NORWAY   (Norway)

^k Mental Health Center Glostrup   (Denmark)

^l UNIVERSITY OF TORONTO   (Canada)

^m TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

ⁿ OSLO UNIVERSITY HOSPITAL   (Norway)

^o UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

more..

Author keywords

Chemotherapy; Hodgkin lymphoma; Pancreatic cancer; Radiotherapy; Second cancer

Indexed keywords

ALKYLATING AGENT; CHLORMETHINE; CYCLOPHOSPHAMIDE; PROCARBAZINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURVIVOR; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PANCREAS CANCER; PRIORITY JOURNAL; RADIATION DOSE; RADIATION FIELD; RISK ASSESSMENT; TUMOR LOCALIZATION; ADVERSE EFFECTS; CHEMICALLY INDUCED; COMPLICATION; NEOPLASMS, RADIATION-INDUCED; PANCREATIC NEOPLASMS; PATHOLOGY; RADIATION RESPONSE; RISK FACTOR;

ADULT; AGED; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, RADIATION-INDUCED; PANCREATIC NEOPLASMS; RADIOTHERAPY; RISK FACTORS;

EID: 84928172425     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu287     Document Type: Article

References (27)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Birdwell SH, Hancock SL, Varghese A et al. Gastrointestinal cancer after treatment of Hodgkin's disease. Int J Radiat Oncol Biol Phys 1997; 37: 67-73.
3. Dores GM, Metayer C, Curtis RE et al. Second malignant neoplasms among longterm survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002; 20: 3484-3494.
4. Hodgson DC, Gilbert ES, Dores GM et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 2007; 25: 1489-1497.
5. Metayer C, Lynch CF, Clarke EA et al. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol 2000; 18: 2435-2443.
6. Shen M, Boffetta P, Olsen JH et al. A pooled analysis of second primary pancreatic cancer. Am J Epidemiol 2006; 163: 502-511.
7. De Bruin ML, Burgers JA, Baas P et al. Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. Blood 2009; 113: 3679-3681.
8. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
9. Stovall M, Weathers R, Kasper C et al. Dose reconstruction for therapeutic and diagnostic radiation exposures: use in epidemiological studies. Radiat Res 2006; 166: 141-157.
10. UNSCEAR. United Nations Scientific Committee on the Effects of Atomic Radiation. Effects of ionizing radiation: UNSCEAR 2006 Report, Volume 1-Report to the General Assembly with Scientific Annexes A and B. Vienna: United Nations 2008.
11. Travis LB, Gospodarowicz M, Curtis RE et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002; 94: 182-192.
12. Breslow NE, Day NE. Statistical Methods in Cancer Research: the Analysis of Case-Control Studies, Vol. 1. Lyon: International Agency for Research on Cancer 1980.
13. Preston DL, Lubin JH, Pierce DA, McConney MA. Epicure: User's Guide. Seattle: HiroSoft International Corporation 1993.
14. Little MP, Stovall M, Smith SA, Kleinerman RA. A reanalysis of curvature in the dose response for cancer and modifications by age at exposure following radiation therapy for benign disease. Int J Radiat Oncol Biol Phys 2013; 85: 451-459.
15. Weiss HA, Darby SC, Doll R. Cancer mortality following X-ray treatment for ankylosing spondylitis. Int J Cancer 1994; 59: 327-338.
16. Preston DL, Ron E, Tokuoka S et al. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res 2007; 168: 1-64.
17. van den Belt-Dusebout AW, Aleman BM, Besseling G et al. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys 2009; 75: 1420-1429.
18. Morton LM, Dores GM, Curtis RE et al. Stomach cancer risk after treatment for Hodgkin lymphoma. J Clin Oncol 2013; 31: 3369-3377.
19. Henderson TO, Oeffinger KC, Whitton J et al. Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. Ann Intern Med 2012; 156: 757-766. W-260.
20. Nottage K, McFarlane J, Krasin MJ et al. Secondary colorectal carcinoma after childhood cancer. J Clin Oncol 2012; 30: 2552-2558.
21. Veiga LH, Bhatti P, Ronckers CM et al. Chemotherapy and thyroid cancer risk: a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev 2012; 21: 92-101.
22. Marselos M, Vainio H. Carcinogenic properties of pharmaceutical agents evaluated in the IARC Monographs programme. Carcinogenesis 1991; 12: 1751-1766.
23. Henderson TO, Rajaraman P, Stovall M et al. Risk factors associated with secondary sarcomas in childhood cancer survivors: a report from the childhood cancer survivor study. Int J Radiat Oncol Biol Phys 2012; 84: 224-230.
24. Specht L, Yahalom J, Illidge T et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 2013; 89: 854-862.
25. Engert A, Plutschow A, Eich HT et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363: 640-652.
26. Townsend W, Linch D. Hodgkin's lymphoma in adults. Lancet 2012; 380: 836-847.
27. Travis LB, Hill DA, Dores GM et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003; 290: 465-475.